BEX1 and glioblastoma: The findings that BEX1 and BEX4 mediate cytoskeleton formation in GBM cells after radiotherapy and treatment with Lat B, a pharmacological candidate, can overcome acquired GBM aggressiveness may lead to a therapeutic strategy.